Our immune system cures us every day from cancer and infection by utilizing multiple clonotypes of T cells (multiple TCR codes) to avoid immune escape. It employs several MHC alleles (multiple antigen codes) to invoke the full power of the immune response. Our system recruits not only “killer” CD8+ cells but also ”helper” CD4+ cells and long term cures are sustained by the establishment of immune T cell memory against certain antigen codes. Continued waves of multiple T cell clonotypes overwhelm the tumor and the persistency of these waves establish long term remission.
Our approach is to recapitulate this approach, our medicines are designed to contain or induce multiple clones of CD4+ and CD8+ cells with effector and memory phenotypes to restore therapeutic immunity, and this is achieved by multiple antigens per clonotype, antigens for MHC Class I and MHC Class II and with the predominant focus on T cells from the periphery with high memory potential.